Form D · Biotechnology
Xilio Therapeutics, Inc.
Waltham, MA · CIK 0001840233
Offering snapshot reported Feb 26, 2021 · SEC filing
- Reported sold
- $95M Offering amount: $95M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 23, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 26, 2021 | Initial | $94,999,989 | No comparison | 17 | SEC filing |
| Jan 21, 2021 | Initial | $50,249,990 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-390683
Source: Form D, filed Feb 26, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Timothy Clackson | Executive |
| Paul Clancy | Director |
| Daniel Curran | Director |
| Peter Dudek | Director |
| Joseph Farmer | Executive |
| David Gardner | Director |
| David Grayzel | Director |
| Andrew Hack | Director |
| Nancy Hong | Director |
| Rachel Humphrey | Director |
| Daniel Lynch | Director |
| Michael Ross | Director |
| Rene Russo | Director, Executive |
| Robert Weisskoff | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
828 Winter Street
Waltham, MA, 02451
Waltham, MA, 02451